Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial.

MLA

Kwak, Soo Heon, et al. “Efficacy and Safety of Enavogliflozin, a Novel SGLT2 Inhibitor, in Korean People with Type 2 Diabetes: A 24‐week, Multicentre, Randomized, Double‐blind, Placebo‐controlled, Phase III Trial.” Diabetes, Obesity & Metabolism, vol. 25, no. 7, July 2023, pp. 1865–73. EBSCOhost, https://doi.org/10.1111/dom.15046.

APA

Kwak, S. H., Han, K. A., Kim, K., Yu, J. M., Kim, E., Won, J. C., Kang, J. G., Chung, C. H., Oh, S., Choi, S. H., Won, K. C., Kim, S. G., Cho, S. A., Cho, B. Y., & Park, K. S. (2023). Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24‐week, multicentre, randomized, double‐blind, placebo‐controlled, phase III trial. Diabetes, Obesity & Metabolism, 25(7), 1865–1873. https://doi.org/10.1111/dom.15046

Chicago

Kwak, Soo Heon, Kyung Ah Han, Kyung‐Soo Kim, Jae Myung Yu, EunSook Kim, Jong Chul Won, Jun Goo Kang, et al. 2023. “Efficacy and Safety of Enavogliflozin, a Novel SGLT2 Inhibitor, in Korean People with Type 2 Diabetes: A 24‐week, Multicentre, Randomized, Double‐blind, Placebo‐controlled, Phase III Trial.” Diabetes, Obesity & Metabolism 25 (7): 1865–73. doi:10.1111/dom.15046.